-
-
-
Fosun Tourism Group Reported Record-High Revenue and Over 40% Profit Growth in the First Half of 2025
2025-08-28
(Shanghai, August 27, 2025) — Fosun International Limited (00656.HK) today announced the interim results of its subsidiary, Fosun Tourism Group (the “Group”), for the six months ended June 30, 2025. During the reporting period, Fosun Tourism Group delivered steady growth, with revenue reaching a historical high and adjusted net profit increasing by over 40% year-on-year.
-
-
-
-
Fosun International Announces 2025 Interim Results: Steady Growth in Core Businesses with Accelerated Innovation and Globalization
2025-08-27
(Hong Kong, Shanghai, 27 August 2025) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”).
-
-
-
-
Fosun Pharma Announces 2025 Interim Results: Enhancing Innovation Efficiency and Steadily Expanding Globally
2025-08-26
(August 26, 2025, Shanghai, China) — On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its operating performance for the first half of 2025 (“the Reporting Period”).
-
-
-
-
Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
2025-08-25
Shanghai, China, August 25, 2025 – Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390.1 million. Operating cash flow reached RMB770.9 million, with an increase of 206.8% YoY, maintaining a steady positive inflow.
-
-
-
-
First Subject Dosed in the US for a Phase 2 International Clinical Trial of Henlius’ PD-L1 ADC HLX43 for NSCLC
2025-08-23
Shanghai, China, August 22, 2025 — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first subject has been dosed in the US for HLX43-NSCLC201, a phase 2 international muticenter clinical trial of HLX43, its innovative programmed death-ligand 1 (PD-L1) targeting antibody-drug conjugate (ADC), for the treatment of patients with advanced non-small cell lung cancer (NSCLC). Henlius is vigorously advancing the global development of HLX43, with an international multi-region phase 2 clinical trial initiated in China, the US, Australia, and Japan. At present, no PD-L1 targeting ADC has been approved for marketing globally.
-
-
-
-
Henlius’ Serplulimab Prescribed for the First Time in Both Europe and India, Marking a Milestone Toward Global Accessibility
2025-08-22
Shanghai Henlius Biotech, Inc. (2696.HK) announced that its self-developed anti-PD-1 monoclonal antibody (mAb) serplulimab was recently prescribed for the first time in both Europe and India. This milestone marks that this Chinese innovative biologic is now in clinical use in Europe as well as the world’s most populous country, further accelerating the global accessibility of innovative biologics.
-
-
-
-
Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning
2025-08-21
HONG KONG, August 20, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; referred to collectively with its subsidiaries as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), and Injectables, alongside other complementary offerings, today announced its unaudited consolidated interim results for the six months ended June 30, 2025 (the "Reporting Period").
-
-
-
-
Fosun Pharma’s Self-Developed Innovative Drug Luvometinib Tablets Gains Breakthrough Therapy Designation in Saudi Arabia
2025-08-19
(August 18, 2025, Shanghai, China)— On August 18, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; SSE: 600196, HKEX: 02196) announced that its self-developed innovative drug Luvometinib Tablets(Chinese trade name:复迈宁®; the “Drug”) has gained Breakthrough Therapy Designation by the Saudi Food and Drug Authority(SFDA) for the treatment of adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms. This milestone marks the acceleration of the Drug’s registration and commercialization process in Saudi Arabia.
-
-
-
-
Henlius Licenses Phase 3 Innovative HER2 ADC from GeneQuantum
2025-08-19
Recently, Shanghai Henlius Biotech, Inc. (2696.HK) has entered into a strategic collaboration with GeneQuantum Healthcare (Suzhou) Co., Ltd. ("GeneQuantum"). As agreed, Henlius will obtain the development and exclusive commercialization rights for the innovative HER2-targeted antibody-drug conjugate (ADC) GQ1005 in China and certain overseas markets. The drug candidate, currently in phase 3 clinical development, is being evaluated for HER2-positive breast cancer.
-